info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
22
Apr
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
20
Apr
CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
7
Apr
CymaBay to Present at the 14th Annual Needham Healthcare Conference
25
Mar
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
24
Mar
CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors
23
Mar
CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
18
Mar
CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
11
Mar
CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
27
Feb
CymaBay to Present at Upcoming Investor Conferences
24
Feb
CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares
<< Previous
1
2
3
4
Next >>
Show All
Scroll
